Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists

Background: The P2Y(12) receptor antagonist selatogrel is being developed for subcutaneous self-administration with a ready-to-use autoinjector at the onset of acute myocardial infarction (AMI) symptoms. The unique pharmacological profile of selatogrel (fast, potent, and short-acting) can bridge the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsin, Chih-hsuan, Dingemanse, Jasper, Henrich, Andrea, Bernaud, Corine, Gehin, Martine, Krause, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527299/
https://www.ncbi.nlm.nih.gov/pubmed/37759765
http://dx.doi.org/10.3390/biom13091365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527299/
https://www.ncbi.nlm.nih.gov/pubmed/37759765
http://dx.doi.org/10.3390/biom13091365

Ejemplares similares